Cargando…

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy

Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa). Several mechanisms have been hypothesized to explain the progression of PCa to CRPC during AD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armandari, Inna, Hamid, Agus Rizal, Verhaegh, Gerald, Schalken, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society (APPS) 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186953/ https://www.ncbi.nlm.nih.gov/pubmed/25325021 http://dx.doi.org/10.12954/PI.14063

Ejemplares similares

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells
por: Migita, Toshiro, et al.
Publicado: (2017)

Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides
por: Luna Velez, Maria V., et al.
Publicado: (2022)

Personalized Management in Low-Risk Prostate Cancer: The Role of Biomarkers
por: Dijkstra, Siebren, et al.
Publicado: (2012)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer
por: Rönnau, C. G. H., et al.
Publicado: (2021)

Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
por: Zhou, Jianfu, et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis
por: Zhang, Wenhui, et al.
Publicado: (2021)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
por: Huhtaniemi, Riikka, et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
por: Aggarwal, Rahul, et al.
Publicado: (2011)

Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2020)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
por: Yausep, Oliver E., et al.
Publicado: (2019)

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
por: El-Amm, Joelle, et al.
Publicado: (2013)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
por: Beer, Tomasz M., et al.
Publicado: (2022)

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
por: Maity, Sankar N., et al.
Publicado: (2016)

Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
por: Amaral, Teresa Maria Santos, et al.
Publicado: (2012)

Targeting the MLL complex in castration resistant prostate cancer
por: Malik, Rohit, et al.
Publicado: (2015)

Targeting hexokinase 2 in castration-resistant prostate cancer
por: Deng, Yibin, et al.
Publicado: (2015)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis
por: Xu, Zhenyu, et al.
Publicado: (2020)

Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration‐resistant prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2020)

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
por: Liu, Hsin-Ho, et al.
Publicado: (2014)

Castration-resistant prostate cancer: systemic therapy in 2012
por: Maluf, Fernando C., et al.
Publicado: (2012)

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
por: Moon, Sue Jin, et al.
Publicado: (2021)

Noncoding RNAs as Novel Biomarkers in Prostate Cancer
por: Rönnau, C. G. H., et al.
Publicado: (2014)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_afc9soac521j6l7ibm74kv8jcu